Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for mosaic NF2-related schwannomatosis has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for mosaic NF2-related schwannomatosis.
10 publications have been identified in PubMed for mosaic NF2-related schwannomatosis. Research spans Review / Meta-Analysis (30%), Diagnostic / Biomarker (20%), and Case Report / Case Series (20%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 3 | 30% |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 5:39 PM UTC
European rare disease database
Testing and diagnosis research
2 |
20% |
Patient case studies | 2 | 20% |
Disease patterns and progression | 2 | 20% |
Laboratory research | 1 | 10% |
Peyre M (2026). [PMID: 41824074](https://pubmed.ncbi.nlm.nih.gov/41824074/). *Hum Genet*. [Epidemiology / Natural History]
Kluwe L (2026). [PMID: 42043598](https://pubmed.ncbi.nlm.nih.gov/42043598/). *Neurogenetics*. [Basic Science / Preclinical]
Nogué C (2025). [PMID: 41286185](https://pubmed.ncbi.nlm.nih.gov/41286185/). *Fam Cancer*. [Review / Meta-Analysis]
Kim TK (2025). [PMID: 40090344](https://pubmed.ncbi.nlm.nih.gov/40090344/). *J Korean Neurosurg Soc*. [Review / Meta-Analysis]
Smith MJ (2025). [PMID: 41052866](https://pubmed.ncbi.nlm.nih.gov/41052866/). *Handb Clin Neurol*. [Review / Meta-Analysis]
Tunkel AE (2024). [PMID: 38527168](https://pubmed.ncbi.nlm.nih.gov/38527168/). *Am J Clin Pathol*. [Case Report / Case Series]
Tamura R (2024). [PMID: 38897938](https://pubmed.ncbi.nlm.nih.gov/38897938/). *Neurol Med Chir (Tokyo)*. [Diagnostic / Biomarker]
Smith MJ (2024). [PMID: 39209702](https://pubmed.ncbi.nlm.nih.gov/39209702/). *J Med Genet*. [Diagnostic / Biomarker]
Plontke SK (2024). [PMID: 38437842](https://pubmed.ncbi.nlm.nih.gov/38437842/). *Otol Neurotol*. [Case Report / Case Series]
Forde C (2024). [PMID: 38925914](https://pubmed.ncbi.nlm.nih.gov/38925914/). *J Med Genet*. [Epidemiology / Natural History]
AI-curated news mentioning mosaic NF2-related schwannomatosis
Updated Aug 20, 2026
A systematic review highlights management strategies for vestibular schwannomas in patients with neurofibromatosis type 2 (NF2)-related schwannomatosis. This research provides insights into treatment options and outcomes for this rare condition.
A recent study evaluates the prognostic and neurological outcomes after surgical intervention for spinal ependymomas associated with neurofibromatosis type 2 (NF2). The findings contribute to understanding treatment impacts on patient quality of life.